Drug Profile
Dihydroergotamine mesylate intranasal - Novartis
Alternative Names: Dihydroergotamine mesylate nasal spray - Novartis; Dihydroergotamine-mesylate; MigranalLatest Information Update: 09 Mar 2022
Price :
$50
*
At a glance
- Originator Novartis
- Class Antimigraines; Ergotamines; Mesylates; Small molecules
- Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Migraine
Most Recent Events
- 07 Mar 2022 Zogenix has been acquired by UCB
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
- 02 Jul 2013 Launched prior to this date for Migraine in Austria (Intranasal)